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Introduction {#sec005}
============

The successful scale-up of antiretroviral therapy (ART) during the last two decades has changed the face of the HIV epidemic, with HIV infection now being considered a chronic disease \[[@pone.0221335.ref001]\]. Adequate treatment has led to reductions in AIDS-related mortality and morbidity \[[@pone.0221335.ref002], [@pone.0221335.ref003]\] and has also improved the life expectancy of people living with HIV (PLHIV), which is now almost identical to the life expectancy observed in the general population \[[@pone.0221335.ref004]--[@pone.0221335.ref006]\]. Nevertheless, increased life expectancy and aging come with new challenges in HIV management. In addition to AIDS-related diseases, PLHIV are exposed to non-HIV diseases that occur independently of the weakness of the immune system \[[@pone.0221335.ref007], [@pone.0221335.ref008]\]. Non-HIV diseases are mostly chronic diseases \[[@pone.0221335.ref007], [@pone.0221335.ref009]--[@pone.0221335.ref012]\]; yet, PLHIV in Africa also suffer from acute diseases, such as malaria and respiratory infections \[[@pone.0221335.ref013], [@pone.0221335.ref014]\].

In resource-limited countries, the Word Health Organization (WHO) recommends the initiation of an ART with a cotrimoxazole prophylaxis for every PLHIV \[[@pone.0221335.ref015]\]. In Côte d\'Ivoire, ART is accessible nation-wide \[[@pone.0221335.ref016]\] and is free of charge in public pharmacies \[[@pone.0221335.ref017]--[@pone.0221335.ref019]\]. This is not the case for the therapeutic management of non-communicable diseases, such as diabetes, hypertension and cancer.

In low-income countries, non-HIV medications may be purchased with or without a prescription. Taking non-HIV medications without a prescription depends on many factors, such as previous successful experiences with the same or similar medications, the cost of non-HIV disease management \[[@pone.0221335.ref019], [@pone.0221335.ref020]\], non-HIV essential medications not usually being available in public health care settings \[[@pone.0221335.ref020]\], the accessibility of health facilities \[[@pone.0221335.ref021]--[@pone.0221335.ref024]\], insufficient health insurance coverage \[[@pone.0221335.ref025], [@pone.0221335.ref026]\] and perceiving that the disease is not serious \[[@pone.0221335.ref021]--[@pone.0221335.ref024]\]. When the use of non-prescribed medications is unjustified and inappropriate, there is an increased risk of drug-drug interactions \[[@pone.0221335.ref027], [@pone.0221335.ref028]\], medication resistances, undesirable side effects and increased health expenditures \[[@pone.0221335.ref029], [@pone.0221335.ref030]\].

There is limited information on the use of non-HIV medications among PLHIV. To our knowledge, seven studies have focused on the use of non-HIV medications among PLHIV in Africa \[[@pone.0221335.ref019], [@pone.0221335.ref026], [@pone.0221335.ref031]--[@pone.0221335.ref034]\]. In three of those studies, non-HIV medications were only listed \[[@pone.0221335.ref026], [@pone.0221335.ref032], [@pone.0221335.ref033]\], and in another one, the focus was on the cost of non ARV medications \[[@pone.0221335.ref019]\]. Only two studies, one from Senegal \[[@pone.0221335.ref031]\] and the other from South Africa \[[@pone.0221335.ref034]\], reported the proportions of PLHIV on ART who used at least one non-HIV medication (85% and 87%, respectively). In these studies, the patients included were on ART less than one year and data was not available on non HIV medication. Moreover, no distinction was made between non-HIV prescribed medications and non-HIV non-prescribed medications. To our knowledge, the use of non-HIV medications either prescribed or not has not been comprehensively studied in Africa. Our study aimed to describe the use of non-HIV medications among PLHIV on ART for at least 12 months in Côte d'Ivoire and to identify factors associated with the use of at least one non-HIV medication.

Materials and methods {#sec006}
=====================

Study design and settings {#sec007}
-------------------------

A cross-sectional study was conducted from April 11th to September 28th, 2016, in six HIV clinics of Côte d'Ivoire. Three of these clinics were located in Abidjan, the economic capital, one in San Pedro in the South-west of the country, one in Bouaké in the Center of the country and the last in Korhogo in the North. These cities were selected in regions with high HIV prevalence. In Abidjan, the three largest HIV clinics were selected. In the three other regions, we selected the clinic with the largest number of PLHIV.

Study population and enrollment of patients {#sec008}
-------------------------------------------

The study population included individuals living with HIV-1, aged 18 years or older, receiving ART for at least one year. Every day during the study period, all eligible individuals attending the participating HIV clinics for a routine follow-up visit were offered to participate in the study. After confirming their eligibility in the medical patient record, the site investigator provided clear information on the study, discussed the information sheet with the participant and fixed an appointment for those who agreed to participate. Three days before the appointment date, each participant received a reminder call from a social worker to confirm the time of the interview.

Data collection {#sec009}
---------------

On the day of interview, the participant signed the consent form before the interview began. During the interview, a social worker collected each participant's demographics and HIV characteristics (WHO clinical stage, history of CD4 count, clinical events, ART regimen and other treatments) using a standardized questionnaire formatted as a case report file (CRF). Data on all medications and traditional and complementary medicine (TCM) products used during the preceding 30 days were also collected. To help in identifying medications used, participants were asked to bring all medications they used. For participants who did not bring their medications, a photo library was shown to help them identify medications they were using. A pharmacist analyzed pictures of all the material brought by the participants (containers, prescription forms, and products) to determine the names, formulations and doses of all medications used by the participants.

Outcome variable {#sec010}
----------------

The main outcome was the use of at least one non-HIV medication. Participants were considered to use at least one non-HIV medication if they reported using any medication other than antiretroviral medications and cotrimoxazole.

Independent variables {#sec011}
---------------------

Patient-related variables included demographic characteristics such as age, sex, have a significant other, education level, being employed or not, monthly income in euros and health insurance coverage. In the context of HIV infection, the term "older" refers to patients aged ≥ 50 years \[[@pone.0221335.ref035], [@pone.0221335.ref036]\]. A participant was considered to have health insurance coverage if he/she reported having medical or/and pharmaceutical insurance coverage. Region was defined according to the localization of the recruiting HIV center: economic capital (for clinics in Abidjan) or hinterland (for clinics in Bouaké, San Pedro and Korhogo).

Health-related variables consisted of data on perceived health status, alcohol consumption and HIV characteristics. Perceived health status was measured using a 6-level Likert scale (excellent to poor). Perceived health status was considered "at least acceptable" when the response was either excellent, very good, good or acceptable; otherwise, it was considered "poor". Alcohol consumption was measured using questions from the WHO STEPS questionnaire (37). Two categories were defined. Alcohol users were those who reported they had used alcohol in the 30 days prior to the interview. The following HIV characteristics were abstracted from the medical records: the date of HIV diagnosis, the initial CD4 count in cells/mm^3^ (\< 200, 200--349, 350--499, ≥ 500), and the WHO clinical stage at diagnosis. The duration of HIV infection was the number of months between the date of HIV diagnosis and the date of the interview.

Concerning treatment-related variables, we measured the use of HIV and non-HIV medications along with traditional and complementary medicines. For HIV medications, current use of ART and cotrimoxazole was abstracted from medical records. ART was classified into two categories: first-line ART (either three nucleoside reverse transcriptase inhibitors or two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor) and second- or third-line ART (two nucleoside reverse transcriptase inhibitors with a protease inhibitor or with an integrase inhibitor) \[[@pone.0221335.ref037], [@pone.0221335.ref038]\]. The duration of ART in months was defined as the time between the date of ART initiation and the date of the interview. Each participant was asked to report the number of ART pills taken each day. Finally, participants were considered to have used a TCM product if they reported having used a TCM within the last 30 days. TCM products were from two main TCM therapeutic modalities: 1) TCM consisting of spiritual and manual treatments, 2) TCM consisting of herbal medicines, veterinary medicines and / or mineral medicines \[[@pone.0221335.ref039]\].

Non-HIV medications were classified according to the WHO Anatomical Therapeutic Chemical Classification (ATC) system \[[@pone.0221335.ref040]\]. For each non-HIV medication, the pharmacological classes were determined. Medications that could not be identified due to a lack of information (such as medications bought in a public market and medications with information written only in Arabic or Chinese) were coded 99999. Natural products that did not have a code in the ATC classification were coded 88888. When a drug had more than one ATC code, we used the code relevant to the self-reported illness. For the choice of ATC codes for generic medications whose International Common Denominations (ICDs) were difficult to identify, we used the national list of the reimbursable medications from ministry of health that contains generic medication names associated with the ICDs for medications.

Participants were considered to have used a TCM product if they reported having used a TCM within the last 30 days.

Statistical analysis {#sec012}
--------------------

Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Pearson Chi square tests were used to compare proportions, Student's t-tests were used to compare means and Wilcoxon tests were used to compare medians. Factors associated with the use of at least one non-HIV medication were identified using a multivariate Poisson regression model. We calculated prevalence ratios (PRs) with their 95% confidence intervals (CIs) (32). To build the model, we included all variables associated with the use of at least one non-HIV medication in the unadjusted analysis (*P* \< 0.2) and used the backward method to identify only variables independently predictive of the use of at least one non-HIV medication with a *P*-value \< 0.05. Sex and age were forced into the final model (33, 34).

Ethical consideration {#sec013}
---------------------

Before being enrolled in the study, each participant received clear information and provided written consent to participate, including the authorization to use personal data for research purposes. The study was approved by the National Ethics Committee for Research in Côte d'Ivoire and the ethics in research committee of CHU de Quebec-Université Laval.

Results {#sec014}
=======

A total of 1,729 HIV patients were approached to participate in the study. Among them, 1,458 (84%) agreed and were included. The reasons for non-participation are summarized in [Table 1](#pone.0221335.t001){ref-type="table"}.

10.1371/journal.pone.0221335.t001

###### Frequency of reported reasons to decline participation (N = 271).

![](pone.0221335.t001){#pone.0221335.t001g}

  Reasons                                                                   N         \%
  ------------------------------------------------------------------------- --------- ------
  Were unavailable for the interview                                        88        32.5
  Could not be reached                                                      41        15.1
  Gave no reason to decline participation                                   20        7.4
  Were not interested by the study                                          20        7.4
  Were outside the city during the study period                             19        7.0
  Did not come to the interview                                             19        7.0
  Either had or a family member had already participated in another study   14        5.2
  Did not use modern and traditional medicine                               13        4.8
  Were not called to make an appointment                                    9         3.3
  Had other reasons[\*](#t001fn001){ref-type="table-fn"}                    28        10.3
  Total                                                                     **271**   100

\* accident, need approbation from family, fear of breaking confidentiality, financial difficulties

Characteristics of the participants according to the region where they were recruited are presented in [Table 2](#pone.0221335.t002){ref-type="table"}. They had a median age of 44 years, IQR (38--50), 27% were aged ≥ 50 years and 736 (50%) were recruited in Abidjan. Approximately 75% of the participants were women. Among the participants, 145 (10%) had health insurance coverage, of which 82% lived in Abidjan. In addition, 776 (53%) reported having used at least one TCM product in the 30 days preceding the interview. Participants attending an HIV clinic in Abidjan had a higher level of education and a higher income than the participants attending a hinterland HIV center.

10.1371/journal.pone.0221335.t002

###### Characteristics of the 1458 participants according to the recruitment setting.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                                                            Total\     Abidjan HIV clinics\   Hinterland HIV clinics\   Pearson chi-squared (χ2) test[^\$^](#t002fn002){ref-type="table-fn"}/ Wilcoxon test[^£^](#t002fn001){ref-type="table-fn"}                       
                                                                                                             N = 1458   N = 736                N = 722                                                                                                                                                                   
  ---------------------------------------------------------------------------------------------------------- ---------- ---------------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------- ----- ------------- ------------
  **Patient-related**\                                                                                                                                                                                                                                                                                                   
  Age (years)                                                                                                                                                                                                                                                                                                            

      Median \[IQR\]                                                                                         44         \[38--50\]             44                        \[39--51\]                                                                                                                  44    \[37--50\]    0.048

      \< 50 years                                                                                            1070       73.4                   525                       71.9                                                                                                                        541   74.9          00.18

      ≥ 50 years                                                                                             388        26.6                   207                       28.1                                                                                                                        181   25.1          

  Sex                                                                                                                                                                                                                                                                                                                    

      Men                                                                                                    381        26.1                   198                       26.9                                                                                                                        183   25.3          0.499

      Women                                                                                                  1077       73.9                   538                       73.1                                                                                                                        539   74.7          

  Body Mass index                                                                                                                                                                                                                                                                                                        

      Underweight (\< 18.5)                                                                                  165        11.3                   71                        09.6                                                                                                                        94    13.0          \<0.0001

      Normal weight (18.5--24.99)                                                                            796        54.6                   373                       50.7                                                                                                                        423   58.6          

      Overweight (25--29.99)                                                                                 359        24.6                   205                       27.9                                                                                                                        154   21.3          

      Obese (≥ 30)                                                                                           138        09.5                   87                        11.8                                                                                                                        51    07.1          

  Have a significant other                                                                                                                                                                                                                                                                                               

      Yes                                                                                                    726        49.8                   360                       48.9                                                                                                                        366   50.7          0.496

      No                                                                                                     732        50.2                   376                       51.1                                                                                                                        356   49.3          

  Education                                                                                                                                                                                                                                                                                                              

      No school                                                                                              454        31.1                   142                       19.3                                                                                                                        312   43.4          \<0.0001

      Primary level                                                                                          433        29.7                   217                       29.5                                                                                                                        216   29.7          

      High school                                                                                            470        32.2                   290                       39.4                                                                                                                        180   24.9          

      \> High school                                                                                         101        6.93                   87                        11.8                                                                                                                        14    01.9          

  Employment                                                                                                                                                                                                                                                                                                             

      Yes                                                                                                    1179       80.9                   620                       84.2                                                                                                                        559   77.4          0.0009

      No                                                                                                     279        19.1                   116                       15.8                                                                                                                        163   22.6          

  Monthly income in euros                                                                                                                                                                                                                                                                                                \<0.0001

      \< 92                                                                                                  964        66.1                   364                       49.4                                                                                                                        600   83.1          

      92--151                                                                                                235        16.1                   183                       24.9                                                                                                                        52    07.2          

      152--304                                                                                               148        10.2                   105                       14.3                                                                                                                        43    06.0          

      ≥ 304                                                                                                  90         06.2                   79                        10.7                                                                                                                        11    01.5          

      Don't Know                                                                                             21         01.4                   05                        00.7                                                                                                                        16    02.2          

  Health insurance coverage                                                                                                                                                                                                                                                                                              

      Yes                                                                                                    145        10.0                   119                       16.2                                                                                                                        26    03.6          \<0.0001

      No                                                                                                     1313       90.0                   617                       83.8                                                                                                                        163   96.4          

  **Health related**                                                                                                                                                                                                                                                                                                     

  Perceived Health Status                                                                                                                                                                                                                                                                                                

      At least acceptable                                                                                    1166       80.0                   610                       82.9                                                                                                                        556   77.0          0.0038

      Poor                                                                                                   281        19.3                   120                       16.3                                                                                                                        161   22.3          

      Missing data                                                                                           11         00.7                   06                        00.8                                                                                                                        05    00.7          

  Hospitalization in the year before interview                                                                                                                                                                                                                                                                           

      Yes                                                                                                    116        09.9                   63                        08.6                                                                                                                        53    07.3          00.39

      No                                                                                                     1313       90.1                   673                       91.4                                                                                                                        696   92.7          

  Alcohol consumption                                                                                                                                                                                                                                                                                                    

      Yes                                                                                                    361        24.8                   284                       38.6                                                                                                                        77    10.7          \<0.0001

      No                                                                                                     1096       75.2                   451                       61.4                                                                                                                        645   89.3          

  HIV duration (months); median \[IQR\]                                                                      91         \[57--120\]            95                        \[58--129\]                                                                                                                 87    \[55--113\]   \<0.0001

      ≤ 120                                                                                                  1096       75.2                   511                       69.4                                                                                                                        585   81            \<0.0001

      \>120                                                                                                  362        24.8                   225                       30.6                                                                                                                        137   19            

  Antiretroviral treatment (ART) duration (months); median \[IQR\]                                           81         \[47--110\]            82                        \[47--116\]                                                                                                                 80    \[44--113\]   \<0.0001

      ≤ 120                                                                                                  1206       82.7                   570                       77.4                                                                                                                        636   88.1          \<0.0001

      \>120                                                                                                  252        17.3                   166                       22.6                                                                                                                        86    11.9          

      Initial CD4 count in cells/mm3; median \[IQR\]                                                                                                                                                                                                                                                                     

      \< 200                                                                                                 685        47.0                   319                       43.3                                                                                                                        366   50.7          0.0001

      200--349                                                                                               393        27.0                   198                       26.9                                                                                                                        195   27.0          

      350--499                                                                                               218        14.9                   138                       18.8                                                                                                                        80    11.1          

      ≥ 500                                                                                                  138        09.5                   78                        10.6                                                                                                                        60    08.3          

      Missing data                                                                                           24         01.6                   03                        00.4                                                                                                                        21    02.9          

                                                                                                             N          \%                     n                         \%                                                                                                                          n     \%            *P* values

  WHO clinical stage                                                                                                                                                                                                                                                                                                     

      I                                                                                                      535        36.7                   255                       34.6                                                                                                                        280   38.8          \<0.0001

      II                                                                                                     521        35.7                   187                       25.4                                                                                                                        334   46.3          

      III or IV                                                                                              380        26.1                   276                       37.5                                                                                                                        104   14.4          

      Missing data                                                                                           01         0.1                    00                        00                                                                                                                          01    0.1           

      Data not available                                                                                     21         1.4                    18                        2.4                                                                                                                         03    0.4           

  **Treatment-related**                                                                                                                                                                                                                                                                                                  

  ART regimen                                                                                                                                                                                                                                                                                                            \<0.0001

      3 NRTIs[^§^](#t002fn003){ref-type="table-fn"} / NNRTIs[^μ^](#t002fn004){ref-type="table-fn"}+2 NRTIs   1182       81.1                   538                       73.1                                                                                                                        644   89.2          

      Others                                                                                                 276        18.9                   198                       26.9                                                                                                                        78    10.8          

  Daily ART pills median \[IQR\]                                                                             02         \[1--10\]              02                        \[1--5\]                                                                                                                    02    \[2--3\]      \<0.0001

      1                                                                                                      284        19.5                   206                       28.0                                                                                                                        78    10.8          \<0.0001

      2                                                                                                      650        44.6                   203                       27.6                                                                                                                        447   61.9          

      \[3--4\]                                                                                               261        17.9                   139                       18.9                                                                                                                        122   16.9          

      ≥ 5                                                                                                    263        18.0                   188                       25.5                                                                                                                        75    10.4          

  Use of cotrimoxazole                                                                                                                                                                                                                                                                                                   

      Yes                                                                                                    535        36.7                   353                       48.0                                                                                                                        182   25.2          \<0.0001

      No                                                                                                     923        63.3                   383                       52.0                                                                                                                        540   74.8          

  Use of traditional and complementary products                                                                                                                                                                                                                                                                          

      Yes                                                                                                    776        53.2                   365                       49.6                                                                                                                        411   56.9          0.005

      No                                                                                                     682        46.8                   371                       50.4                                                                                                                        311   43.1          

  Use at least one non-HIV medication                                                                                                                                                                                                                                                                                    \<0.0001

      Yes                                                                                                    696        47.7                   400                       54.3                                                                                                                        296   41.0          

      No                                                                                                     762        52.3                   336                       45.7                                                                                                                        426   59.0          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^£^Pearson Chi square tests were used to compare proportions

^\$^Wilcoxon tests were used to compare medians

^§^NRTIs nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)

^μ^ NNRTIs Non-nucleoside Reverse Transcriptase Inhibitor, IQR: interquartile Range.

HIV medications use {#sec015}
-------------------

The median ART duration was 81 months (IQR: 47--110), with most participants (n = 1,182; 81%) on a first-line ART regimen. The median number of ART pills taken daily was 2 (IQR: 2--3), with 263 (18%) participants taking ≥ 5 ART pills. A total of 535 (37%) patients reported using cotrimoxazole in addition to ART, with the proportion of PLHIV using cotrimoxazole being higher in Abidjan than in the hinterland (48% vs. 25%, *P* = \<0.0001).

Non-HIV medications use {#sec016}
-----------------------

A total of 696 (48%) participants reported using at least one non-HIV medication. Among them, 319 (46%) reported using one medication, 169 (24%) two medications, 95 (14%) three medications and 113 (16%) ≥ four medications. The median number of non-HIV medications per person was two (IQR: 1--3). Among users of non-HIV medications, 284 (41%) used only non-prescribed medications (median: 1; IQR: 1--2), 318 (46%) used only prescribed medications (median: 2; IQR: 1--3) and 94 (13%) used both prescribed and non-prescribed medications (median: 3; IQR: 2--5). Concerning non-communicable disease, the proportions of users of non-HIV medications for the treatment of cardiovascular disease and diabetes were 5% (N = 68), and 1.1% (N = 16), respectively.

Pharmacologic classes of non-HIV medications {#sec017}
--------------------------------------------

Overall, the number of non-HIV medications reported to be used by the 696 participants totaled 1,519 ([Table 3](#pone.0221335.t003){ref-type="table"}), of which 969 (64%) were prescribed. Among the 1,519 reported non-HIV medications, 397 (26%) were from the nervous system class (reported by 349 (24%) participants), and 260 (17%) were from the alimentary tract and metabolism class (reported by 214 (15%) participants). Among the 550 non-HIV non-prescribed medications, 210 (38%) were analgesics, with the majority being non-opioid medications (used by 177 (12%) participants), along with 47 (9%) antibacterial medications (used by 43 (3%) participants) and 44 (8%) anti-inflammatory and anti-rheumatic medications (used by 41 (3%) participants).

10.1371/journal.pone.0221335.t003

###### Anatomical, Therapeutic and Chemical (ATC) classification of non-HIV medications used according to whether or not they were prescribed.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        Total\       Medication prescribed\   Medication not prescribed\                         
                                                                                        (N = 1519)   (n = 969)                (n = 550)                                          
  ------------------------------------------------------------------------------------- ------------ ------------------------ ---------------------------- ----------- --------- -----------
  **A: Alimentary tract and metabolism**                                                **260**      **17.12**                **162**                      **18.18**   **78**    **14.18**

      A01: Stomatological preparations                                                  07           0.46                     07                           0.31        00        0.00

      A02: Medications for acid related disorders                                       33           2.17                     24                           2.48        09        1.64

      A03: Drugs for functional gastrointestinal disorders                              13           0.86                     11                           1.14        02        0.36

      A04: Antiemetic and antinauseants                                                 02           0.13                     02                           0.21        00        0.00

      A05: Bile and live therapy                                                        04           0.26                     04                           0.41        00        0.00

      A06: Drugs for constipation                                                       03           0.20                     02                           0.21        01        0.18

      A07: Antidiarrheal, intestinal anti-inflammatory/anti-infective agents            09           0.59                     07                           0.72        02        0.36

      A10: Medications used in diabetes                                                 20           1.32                     20                           2.06        00        0.00

      A11: Vitamins                                                                     60           3.95                     41                           4.2         19        3.45

      A12: Mineral supplements                                                          88           8.79                     49                           5.06        39        7.09

  **B: Blood and blood forming organs**                                                 **61**       **4.02**                 **53**                       **5.47**    **08**    **1.45**

      B01: Antithrombotic agents                                                        04           0.26                     03                           0.31        01        0.18

      B03: Anti-anemic drugs                                                            57           3.75                     50                           5.16        07        1.27

  **C: Cardiovascular system**                                                          **79**       **5.20**                 **72**                       **7.93**    **07**    **1.27**

      C01: Cardiac therapy                                                              07           0.46                     06                           0.62        10        0.18

      C02: Antihypertensive                                                             04           0.26                     02                           0.21        02        0.36

      C03 Diuretics                                                                     05           0.33                     05                           0.52        00        00

      C05: Vasoprotectives                                                              07           0.46                     05                           0.52        02        0.36

      C07: Beta blocking agents                                                         12           0.79                     12                           1.24        00        0.00

      C08: Calcium channel blockers                                                     10           0.66                     10                           1.03        00        0.00

      C09: Agents acting on the renin (angiotensin system)                              24           1.58                     24                           2.48        00        0.00

      C10: Lipid modifying agents                                                       10           0.66                     08                           0.83        02        0.36

  **D: Dermatologic drugs**                                                             **24**       **1.58**                 **18**                       **1.86**    **6**     **1.09**

      D01: Antifungals for dermatological use                                           06           0.39                     05                           0.52        01        0.18

      D02: Emollients and protectives                                                   01           0.07                     01                           0.10        00        0.00

      D06: Antibiotics and chemotherapeutics for dermatological use                     02           0.13                     01                           0.10        01        0.18

      D07: Topical dermatological corticosteroids                                       09           0.59                     06                           0.62        03        0.55

      D08: Antiseptics and disinfectants drugs                                          03           0.20                     03                           0.31        00        0.00

      D10: Anti-acne preparations                                                       01           0.07                     0                            0.00        01        0.18

      D11: Other dermatological preparations                                            02           0.13                     2                            0.21        00        0.00

  **G: Genitourinary system and reproductive hormones**                                 **24**       **1.58**                 **19**                       **1.96**    **05**    **0.91**

      G01: Gynecological anti-infectives and antiseptics                                09           0.59                     07                           0.72        02        0.36

      G03: Sex hormones and modulators of the genital system                            14           0.92                     11                           1.14        03        0.55

      G04: Urologicals                                                                  01           0.07                     01                           0.10        00        0.00

  **H: Systemic hormonal preparations, excluding reproductive hormones and insulins**   **10**       **0.66**                 **09**                       **0.93**    **01**    **0.18**

      H02: Corticosteroids systemic                                                     10           0.66                     09                           0.93        01        0.18

  **J: Anti-infectives for systemic use**                                               **144**      **9.48**                 **97**                       **10.01**   **47**    **8.55**

      J01: Antibacterial drugs                                                          135          8.89                     88                           9.08        47        8.55

      J02: Antimycotic drugs                                                            07           0.46                     07                           0.72        00        0.00

      J05: Antivirals for systemic use                                                  02           0.13                     02                           0.21        00        0.00

  **M: Musculoskeletal system**                                                         **114**      **7.50**                 **68**                       **7.02**    **48**    **8.36**

      M01: Anti-inflammatory and antirheumatic drugs                                    100          6.58                     56                           5.78        44        8.00

      M02 Topical products for joint and muscular pain                                  04           0.26                     03                           0.31        01        0.18

      M03: Muscle relaxants                                                             08           0.53                     07                           0.72        01        0.18

      M09: Other drugs for disorders of the musculo-skeletal system                     02           0.13                     02                           0.21        00        0.00

  **N: Nervous system**                                                                 **397**      **26.14**                **183**                      **18.09**   **214**   **38.91**

      N02: Analgesic drugs                                                              367          24.16                    157                          16.20       210       38.18

      N03: Antiepileptics                                                               03           0.20                     03                           0.31        00        0.00

      N05: Psycholeptics drugs                                                          14           0.92                     11                           1.14        03        0.55

      N06: Psychoanaleptics                                                             11           0.72                     10                           1.03        01        0.18

      N07: Other nervous system drugs                                                   02           0.13                     02                           0.21        00        0.00

  **P: Antiparasitic products, insecticides and repellents**                            **165**      **10.86**                **118**                      **12.18**   **47**    **8.55**

      P01: Antiprotozoal drugs                                                          130          8.56                     92                           9.49        38        6.91

      P02: Anthelmintic drugs                                                           35           2.30                     26                           2.68        09        1.69

  **R: Respiratory system**                                                             **159**      **10.47**                **102**                      **10.53**   **57**    **10.36**

      R01: Nasal preparations                                                           45           2.96                     26                           3.45        19        2.68

      R02: Throat drugs                                                                 03           0.20                     03                           0.31        00        0.00

      R03: Drugs for obstructive airway diseases                                        09           0.59                     07                           0.72        02        0.36

      R05: Cough and cold drugs                                                         35           2.30                     25                           2.58        10        1.82

      R06: Antihistamines for systemic use                                              64           4.21                     41                           4.23        23        4.18

      R07/ Other respiratory system products                                            03           0.20                     00                           0.00        03        0.55

  **S: Sensory organs**                                                                 **30**       **1.97**                 **27**                       **2.79**    **03**    **0.55**

      S01: Ophthalmological drugs                                                       27           1.78                     25                           2.58        02        0.36

      S02: Otologicals                                                                  03           0.20                     02                           0.21        01        0.18

  **V: Various ATC structures**                                                         **4**        **0.26**                 **4**                        **0.41**    **0**     **0.00**

      V06: General nutrients                                                            4            0.26                     4                            0.41        0         0.00

  **Medication not identified**                                                         **37**       **2.44**                 **23**                       **4.18**    **14**    **1.44**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Factors associated with the use of at least one non-HIV medication {#sec018}
------------------------------------------------------------------

In the multivariate Poisson regression, after adjusting for age and sex, seven factors were statistically associated with the use of non-HIV medication ([Table 4](#pone.0221335.t004){ref-type="table"}). Individuals who had a high school education level (PR = 1.17 \[95% CI = 1.02--1.35\] vs. unschooled), a monthly income between 152 and 304 euros (PR = 1.31 \[95% CI = 1.12--1.53\] vs. \< 92euros), a poor (vs. at least acceptable) perceived health status (PR = 1.30 \[95% CI = 1.06--1.46\]), a WHO clinical stage II or III/IV (PR = 1.24 \[95% CI = 1.08;1.41\]; PR = 1.22 \[95% CI = 1.06;1.40\]), and those who were TCM product users (vs. no (PR = 1.22 \[95% CI = 1.10--1.37\]) were more likely to report the use of at least one non-HIV medication. Participants recruited in a hinterland HIV clinic (PR = 0.72 \[95% CI = 0.64--0.82\]) and cotrimoxazole users (vs. not) (PR = 0.77 \[95% CI = 0.67--0.84\]) were less likely to report the use at least one non-HIV medication.

10.1371/journal.pone.0221335.t004

###### Associations between patient-related, health-related and treatment-related characteristics and use of at least one non-HIV medication (N = 1458).

![](pone.0221335.t004){#pone.0221335.t004g}

  Characteristics                                 Use of at least one non-HIV medication   Crude prevalence ratios   95% Confidence Intervals (CI)   *P* values   Adjusted prevalence ratios   95% CI           *P* values                           
  ----------------------------------------------- ---------------------------------------- ------------------------- ------------------------------- ------------ ---------------------------- ---------------- ------------ ------ ---------------- ----------
  **Patient-related**                                                                                                                                                                                                                                
  Age (years)                                                                                                                                                                                                                                        
      \< 50                                       518                                      74.4                      552                             72.4         0.96                         \[0.85--1.10\]   0.40         0.90   \[0.84--1.09\]   0.59
      ≥ 50                                        178                                      25.6                      210                             27.6         1                            1                             1      1                
  Sex                                                                                                                                                                                                                                                
      Men                                         173                                      24.9                      208                             27.3         1.07                         \[0.94--1.21\]   0.30         1.12   \[0.97--1.29\]   0.12
      Women                                       523                                      75.1                      554                             72.7         1                                                                                  
  HIV clinics                                                                                                                                                                                                                                        
      Hinterland                                  296                                      42.5                      426                             55.9         0.75                         \[0.68--0.84\]   \<0.001      0.72   \[0.64--0.82\]   \<0.001
      Abidjan                                     400                                      57.5                      336                             44.1         1                                                                                  
  Have a significant other                                                                                                                                                                                                                           
      Yes                                         362                                      52.0                      364                             47.8         1                                                                                  
      No                                          334                                      48.0                      398                             52.2         0.91                         \[0.82--1.01\]   0.10                                 
  Education                                                                                                                                                                                                                                          
      No school                                   184                                      26.4                      270                             35.4         1                                                                                  
      Primary level                               199                                      28.6                      234                             30.7         1.13                         \[0.97--1.32\]   0.103        1.04   \[0.89--1.21\]   0.62
      Secondary school                            249                                      35.8                      221                             29.0         1.31                         \[1.14--1.50\]   0.0002       1.17   \[1.02--1.35\]   0.026
      \> High school                              94                                       9.2                       37                              4.9          1.56                         \[1.30--1.88\]   \<0.0001     1.23   \[0.99--1.50\]   0.055
  Monthly Income in Euros                                                                                                                                                                                                                            
      \< 92                                       437                                      62.8                      527                             69.2         1                                                          1                       
      92--151                                     107                                      15.4                      128                             16.8         1.00                         \[0.86--1.17\]   0.95         0.91   \[0.77--1.06\]   0.24
      152--304                                    92                                       13.2                      56                              7.3          1.37                         \[1.19--1.58\]   \< 0.0001    1.31   \[1.12--1.53\]   0.0006
      ≥ 304                                       52                                       7.5                       38                              5.0          1.27                         \[1.05--1.54\]   0.01         1.11   \[0.88--1.41\]   0.36
      Don't Know                                  8                                        1.1                       13                              1.7                                                                                             
  Insurance coverage                                                                                                                                                                                                                                 
      Yes                                         88                                       12,6                      57                              7.5          1.31                         \[1.14--1.51\]   0.0002                               
      No                                          608                                      87.4                      705                             92.5         1                                                                                  
  **Health-related**                                                                                                                                                                                                                                 
  Perceived Health Status                                                                                                                                                                                                                            
      Poor                                        500                                      71.9                      596                             78.2         1.38                         \[1.23--1.55\]   \< 0.0001    1.30   \[1.16--1.46\]   \<0.0001
      At least acceptable                         195                                      28.0                      166                             21.8         1                                                                                  
      Missing data                                1                                        0.1                                                                                                                                                       
  Time since HIV diagnosis (months)               96                                       12--235                   85                              12--270                                                                                         
      ≤ 120                                       498                                      71.5                      598                             78.5         0.83                         \[0.74--0.93\]   0.0014                               
      \> 120                                      198                                      28.5                      164                             21.5                                                                                            
  Initial CD4 count in cells/mm^3^;                                                                                                                                                                                                                  
      \< 200                                      334                                      48.0                      351                             46.0         1.004                        \[0.83--1.21\]   0.96                                 
      200--349                                    186                                      26.7                      207                             27.2         0.97                         \[0.78--1.19\]   0.80                                 
      350--499                                    96                                       13.8                      122                             16.0         0.90                         \[0.72--1.14\]   0.40                                 
      ≥ 500                                       67                                       9.6                       71                              9.3          1                                                                                  
      Missing data                                13                                       1.9                       11                              1.5                                                                                             
  WHO HIV clinical stage                                                                                                                                                                                                                             
      I                                           219                                      31.5                      316                             41.5         1                                                                                  
      II                                          265                                      38.0                      256                             33.6         1.24                         \[1.09--1.42\]   0.0013       1.24   \[1.08--1.41\]   0.0017
      III or IV                                   205                                      29.5                      205                             23.0         1.32                         \[1.15--1.81\]   \<0.0001     1.22   \[1.06--1.40\]   0.005
      Missing data                                0                                        00.0                      1                               00.1                                                                                            
      Data not available                          7                                        01.0                      14                              01.8                                                                                            
  **Treatment-related**                                                                                                                                                                                                                              
  Use of cotrimoxazole                                                                                                                                                                                                                               
      No                                          462                                      66.4                      461                             60.5         1                                                                                  
      Yes                                         234                                      33.6                      301                             39.5         0.87                         \[0.78--0.98\]   0.022        0.77   \[0.69--0.87\]   \<0.0001
  Use of traditional and complementary products                                                                                                                                                                                                      
      Yes                                         407                                      58.5                      369                             48.4         1.24                         \[1.11--1.38\]   0.0001       1.22   \[1.10--1.37\]   \<0.0001
      No                                          289                                      41.5                      393                             51.6         1                                                                                  

Discussion {#sec019}
==========

This is one of the first studies performed in West Africa describing the use of non-HIV medications among PLHIV on ART. In summary, 48% of PLHIV reported using at least one non-HIV medication, and 54% of them used non-prescribed drugs. The most reported classes of non-HIV medication used were the nervous system class (26%) and the alimentary tract and metabolism class (17%). Non-prescribed non-HIV medications represented 36% of 1,519 non-HIV medications, of which 39% were analgesic medications. Factors associated positively with the use of non-HIV medication were having a high level of school education, a monthly income between 152 and 304 euros, using TCM products, having a poor perceived health status and having a WHO stage II or III/IV. However, being treated in an HIV hinterland clinic and using cotrimoxazole were factors negatively associated with the use of non-HIV medication.

The proportion of PLHIV using non-HIV medications (48%) we observed was lower than those observed in most of the previous studies in both high- \[[@pone.0221335.ref041]--[@pone.0221335.ref050]\] and low-income countries \[[@pone.0221335.ref031], [@pone.0221335.ref034]\], where the proportions varied between 68% and 95%, distributed as follows: 68% in Switzerland \[[@pone.0221335.ref046], [@pone.0221335.ref050]\], 75% in Canada \[[@pone.0221335.ref045]\], 82% in Spain \[[@pone.0221335.ref042]\], 83% in USA \[[@pone.0221335.ref043]\], 85% in Senegal \[[@pone.0221335.ref031]\] 85% in USA \[[@pone.0221335.ref044]\], 87% in South Africa \[[@pone.0221335.ref034]\], 89% in Canada \[[@pone.0221335.ref041]\], 91% in Canada \[[@pone.0221335.ref047]\], 93% in USA \[[@pone.0221335.ref048]\] and 95% in Canada \[[@pone.0221335.ref049]\]. This difference might be explained by different reasons. Older PLHIV face many aging-related diseases \[[@pone.0221335.ref051], [@pone.0221335.ref052]\]. Our population was younger than those included in the high-income countries studies. Indeed, 32% \[[@pone.0221335.ref043], [@pone.0221335.ref047], [@pone.0221335.ref050]\] to 100% \[[@pone.0221335.ref042]\] of patients from high-income countries were over 50 years old, whereas in our study, only 27% were over 50 years old. Third, in the studies in high-income countries, 79% \[[@pone.0221335.ref043], [@pone.0221335.ref048]\] to 100% \[[@pone.0221335.ref045]\] of participants had public or private drug insurance, whereas only 10% of our study participants had such insurance, which may limit access to non-HIV medications.

One study conducted in Africa reported proportions of non-HIV medication users \[[@pone.0221335.ref031]\]. This was a retrospective study conducted in Senegal including 331 PLHIV who initiated ART between 2009 and 2011 and were followed until March 2012. PLHIV in the first year of ART initiation represented 43% of the participants. After a mean duration of 11.4 months on ART, 85% of patients received at least one prescription for a non-ART medication. In this study, the most frequently prescribed non-ART medications were cotrimoxazole (78.9% of patients), iron (33.2%), vitamins (21.1%) and antibiotics (19.6%).

Regarding non-HIV medication findings, in Côte d'Ivoire, before the availability of ART, in a cohort study, Nombela et al. reported 58,776 medications prescribed among 592 PLHIV. The most used classes of medication were the anti-infectious (32.8%) and pain medication (22.9%) classes \[[@pone.0221335.ref032]\]. In our study, the most common non-HIV medications used by participants were from the nervous system class (26%), as in some studies conducted in high-income countries \[[@pone.0221335.ref042], [@pone.0221335.ref047], [@pone.0221335.ref048]\]. However, we observed that the proportion of nervous system class medication users (24%) in our study was lower than the proportions observed in the USA (32%) \[[@pone.0221335.ref044]\], (52% \[[@pone.0221335.ref048]\]), Spain (44% \[[@pone.0221335.ref042]\]) and Canada (58% \[[@pone.0221335.ref047]\]). This difference could be explained by a greater diversity of therapeutic classes (antidepressants/antipsychotics/anxiolytics/analgesics) used in high-income countries, unlike in our study, where 96% of users of nervous system medications took analgesics. Indeed, accessibility to nervous system classes other than analgesics is limited in low-resource countries \[[@pone.0221335.ref053]\]. Furthermore, mental health services are only accessible in specialized health facilities.

The proportions of users of medications for the treatment of cardiovascular diseases and diabetes in our study were 5% and 1%, respectively, which are lower than those found in high-income countries (with the percentages of cardiovascular medication users being 43% \[[@pone.0221335.ref047]\], 26% \[[@pone.0221335.ref042]\], and 42% \[[@pone.0221335.ref044]\] and the percentage of diabetes medication users being 11% \[[@pone.0221335.ref044], [@pone.0221335.ref048]\]). This difference could be explained by the fact that diagnosis of non-communicable diseases in low-income countries is not routinely performed during HIV visits and by the low proportion of old PLHIV in our study. Therefore, we hypothesize that in our study, PLHIV with potentially non-communicable diseases may suffer from cardiovascular disease or diabetes, but they are not aware of their condition because they do not have access to diagnostics. The users of sex hormones and modulators of the genital system represented 9% \[[@pone.0221335.ref047]\] and 19% \[[@pone.0221335.ref044]\] in the PLHIV populations of high-income countries. In our study, only 0.9% used these drugs.

The use of a prescription medication without a prescription from a health professional was observed in our PLHIV population. Antibiotics and anti-malaria medications were used without prescription by 3.0% and 2.5% of participants, respectively. Individuals using those drugs without a prescription have likely not been exposed to appropriate diagnostic tests. The misuse of antibiotics or malaria medications can increase the risk of resistance to these medications and of drug-drug interactions \[[@pone.0221335.ref047], [@pone.0221335.ref054]\].

Seven factors were associated with the use of non-HIV medications. Some of these factors, such as WHO advanced clinical stage \[[@pone.0221335.ref031]\] and high level of education and high income \[[@pone.0221335.ref019]\], are in line with those that have been reported in previous studies. In our study, we observed that PLHIV living in Abidjan had higher incomes and access to non-HIV medications compared with PLHIV from the hinterland HIV clinics.

This study provides insight on the use of non-HIV medication by PLHIV on ART in West Africa. To our knowledge, this is the first study conducted in Africa that describes the extent to which non-HIV medications used were prescribed or not.

Our study has some limitations. First, we could not include patients who did not show up for their HIV follow-up. It is possible that these people were sicker than our participants. Therefore, we may have underestimated the proportion of non-HIV medication users. Second, the use of non-HIV medication was self-reported, which is susceptible to a memory bias. Therefore, the proportion of people using non-prescribed non-HIV medications may have been underestimated. Similarly, PLHIV who forgot their medications or prescriptions at home may have under-reported the use of non-HIV medications. If these medications were not actually medications, the proportion of non-HIV medications would be underestimated. Moreover, answers to questions related to income and health status perception may have suffered from social desirability bias. Next, since our study was conducted in only four regions in Côte d'Ivoire, our results are not generalizable to the entire population of PLHIV on ART in Côte d'Ivoire.

Conclusion {#sec020}
==========

In this study, we observed that approximately 50% of PLHIV on ART for at least one year used a non-HIV medication. More than half of them used non-HIV medications that were not prescribed. The results of this study suggest that healthcare professionals should pay attention to the needs of PLHIV in terms of non-HIV medications, particularly for patients living in Abidjan and those who are not using cotrimoxazole.
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